Abstract

Objectives: To demonstrate adequate skin adhesion of a new once-daily rotigotine transdermal patch (ROT-TDS) compared to the originator product (reference) in patients with Parkinson’s disease (PD).
Materials and methods: Pharmacokinetic bioequivalence (PK BE) was assessed with the 4 mg/24h patches in healthy adults in a single-/multiple-dose, crossover trial. The trial investigating skin adhesion in PD patients (stable dose ≥ 8 mg/day rotigotine) was performed with the 8 mg/24h patches as a multiple-dose, crossover trial (4 alternating once-daily patch applications). Skin status (seborrhea, sweating) was characterized at screening. Adhesion was assessed 5 minutes after application and 5 minutes before removal of each patch. Systemic safety and skin irritation/sensitization were monitored.
Results: ROT-TDS was bioequivalent to the reference product in the PK BE trial in 48 randomized healthy subjects. In the skin adhesion trial in 43 randomized PD patients, the cumulative mean percentage of adhesion (90% CI) at the end-of-dosing interval was 92.948% (90.156 – 95.740%) for ROT-TDS and 90.471% (87.574 – 93.367%) for the reference. For ROT-TDS, 80.23% of patches were ≥ 90% adhered at the end-of-dosing interval, while this was the case for 67.44% of the reference patches. Safety and skin tolerability of both products were comparable; the most frequent treatment-related adverse event was application-site pruritus for both treatments at comparable extent.
Conclusion: ROT-TDS – with shown BE to the originator reference product – displayed similar safety and local tolerability as the reference product in patients with PD. The results show a trend to improved skin adhesion of the new patch compared to the reference in the target population.

Author Details

Authors

• Wolfgang H. Jost¹
• Maggie Wang²
• Gabriel Wauer³
• Annika Dax⁴
• Ralph-Steven Wedemeyer^{4, 5}
• Barbara Schug⁴
• André Warnke⁴
• Ana Leblanc⁶
• Bjoern Schurad³

Departments

• ¹ Parkinson-Klinik Ortenau, Wolfach, Germany,
• ² Luye Pharma Switzerland AG, Basel, Switzerland,
• ³ Luye Pharma AG, Miesbach,
• ⁴ SocraTec R&D GmbH, Oberursel,
• ⁵ SocraMetrics GmbH, Erfurt, Germany, and
• ⁶ BlueClinical Phase
• ¹ , Hospital de Prelada, Porto, Portugal

Address

Bjoern Schurad, PhD
Luye Pharma AG
Am Windfeld 35
83714 Miesbach, Germany
Email: [email protected]

Log in for Subscribers

Citation